GlaxoSmithKline (GSK) has announced its acquisition of a US biopharmaceutical company, RAPT Therapeutics, for a sum of 2.2 billion dollars. This strategic move marks GSK’s first bolt-on acquisition under the
GlaxoSmithKline (GSK) has announced its acquisition of a US biopharmaceutical company, RAPT Therapeutics, for a sum of 2.2 billion dollars. This strategic move marks GSK’s first bolt-on acquisition under the
GSK, one of Britain’s foremost pharmaceutical giants, has announced an ambitious plan to invest $30 billion in the United States over the coming five years. This investment will bolster research






